Tvardi Therapeutics (NASDAQ:TVRD) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen cut shares of Tvardi Therapeutics (NASDAQ:TVRD) from a sell rating to a strong sell rating in a research note released on Sunday,Wall Street Zen reports.

Several other research firms have also recently issued reports on TVRD. HC Wainwright initiated coverage on Tvardi Therapeutics in a research report on Monday, June 8th. They set a “buy” rating and a $9.00 price objective for the company. Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday, July 8th. BTIG Research lowered their price target on Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Piper Sandler upgraded shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price target on the stock in a research note on Wednesday, July 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Tvardi Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Tvardi Therapeutics Trading Down 3.1%

Shares of TVRD opened at $1.75 on Friday. Tvardi Therapeutics has a twelve month low of $1.50 and a twelve month high of $43.65. The firm’s fifty day simple moving average is $2.29 and its 200-day simple moving average is $3.00. The firm has a market capitalization of $23.28 million, a price-to-earnings ratio of -0.63 and a beta of 0.32.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, analysts predict that Tvardi Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tvardi Therapeutics

Several large investors have recently modified their holdings of TVRD. GSA Capital Partners LLP purchased a new position in shares of Tvardi Therapeutics during the second quarter worth approximately $34,000. Arax Advisory Partners raised its position in Tvardi Therapeutics by 277.2% in the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after purchasing an additional 6,173 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in Tvardi Therapeutics in the 2nd quarter valued at $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Tvardi Therapeutics in the 2nd quarter valued at $43,000. Finally, HRT Financial LP acquired a new stake in Tvardi Therapeutics during the 4th quarter worth $47,000. 44.66% of the stock is owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.